Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
06 10 2022
06 10 2022
Historique:
received:
19
05
2022
accepted:
02
09
2022
entrez:
6
10
2022
pubmed:
7
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6-11.5) and 56.8% (95% CI, 56.3-57.3) in the period 8-59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9-80.7) and 86.0% (95% CI, 84.5-87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.
Identifiants
pubmed: 36202800
doi: 10.1038/s41467-022-33169-0
pii: 10.1038/s41467-022-33169-0
pmc: PMC9537178
doi:
Substances chimiques
COVID-19 Vaccines
0
Vaccines, Inactivated
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5536Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Nat Med. 2022 Apr;28(4):838-843
pubmed: 35140406
Epidemiology. 2022 Jul 1;33(4):450-456
pubmed: 35384900
Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
Clin Infect Dis. 2022 Apr 28;74(8):1382-1389
pubmed: 34282839
MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):255-263
pubmed: 35176007
Cad Saude Publica. 2020 Apr 22;36(4):e00070120
pubmed: 32321075
Int J Epidemiol. 2016 Dec 1;45(6):2052-2059
pubmed: 26979985
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
BMJ. 2022 Jun 13;377:e070102
pubmed: 35697361
Am J Epidemiol. 2022 Mar 24;191(5):800-811
pubmed: 35081612
Epidemiol Infect. 2019 Nov 27;147:e306
pubmed: 31774051
N Engl J Med. 2022 May 12;386(19):1804-1816
pubmed: 35263534
NPJ Vaccines. 2021 Apr 12;6(1):51
pubmed: 33846340
N Engl J Med. 2021 Oct 7;385(15):1431-1433
pubmed: 34496195
Nature. 2022 Jan;601(7893):311
pubmed: 35027748
BMJ. 2021 Aug 20;374:n2015
pubmed: 34417194
Nat Med. 2022 Mar;28(3):486-489
pubmed: 35051989
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 Oct 7;385(15):1355-1371
pubmed: 34496194
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
Lancet Infect Dis. 2022 Apr;22(4):483-495
pubmed: 34890537
Lancet Infect Dis. 2022 Oct;22(10):1435-1443
pubmed: 35850128
Lancet. 2022 Feb 5;399(10324):521-529
pubmed: 35074136
Epidemiology. 2020 Jan;31(1):43-64
pubmed: 31609860
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Am J Epidemiol. 2016 Sep 1;184(5):345-53
pubmed: 27587721
Nat Med. 2022 Mar;28(3):481-485
pubmed: 35051990
Lancet Glob Health. 2022 Jun;10(6):e798-e806
pubmed: 35472300
Clin Infect Dis. 2022 Aug 24;75(1):e822-e826
pubmed: 34915551
Epidemiology. 2021 Jul 1;32(4):508-517
pubmed: 34001753